Sara Tulipani1,2, Jules Griffin3,4, Magali Palau-Rodriguez1, Ximena Mora-Cubillos1, Rosa M Bernal-Lopez5,6, Francisco J Tinahones2,6, Barbara E Corkey7, Cristina Andres-Lacueva1. 1. Department of Nutrition, Food Sciences and Gastronomy, Biomarkers & Nutrimetabolomic Lab, XaRTA, INSA, Faculty of Pharmacy and Food Science, University of Barcelona, Barcelona, Spain. 2. Biomedical Research Institute (IBIMA), Service of Endocrinology and Nutrition, Malaga Hospital Complex (Virgen de la Victoria), University of Malaga, Malaga, Spain. 3. MRC Human Nutrition Research, Elsie Widdowson Laboratory, Cambridge, UK. 4. Department of Biochemistry and the Cambridge Systems Biology Centre, University of Cambridge, Cambridge, UK. 5. Biomedical Research Institute (IBIMA), Service of Internal Medicine, Malaga Hospital Complex (Hospital Regional Universitario de Malaga), University of Malaga, Malaga, Spain. 6. CIBER Fisiopatología de la Obesidad y Nutrición (CIBERobn), Instituto de Salud Carlos III (ISCIII), Madrid, Spain. 7. School of Medicine, Obesity Research Center, Boston University, Boston, Massachusetts, USA.
Abstract
OBJECTIVE: To review the metabolomic studies carried out so far to identify metabolic markers associated with surgical and dietary treatments for weight loss in subjects with obesity. METHODS: The Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines were followed. RESULTS: Thirty-two studies successfully met the eligibility criteria. The metabolic adaptations shared by surgical and dietary interventions mirrored a state of starvation ketoacidosis (increase of circulating ketone bodies), an increase of acylcarnitines and fatty acid β-oxidation, a decrease of specific amino acids including branched-chain amino acids (BCAA) and (lyso)glycerophospholipids previously associated with obesity, and adipose tissue expansion. The metabolic footprint of bariatric procedures was specifically characterized by an increase of bile acid circulating pools and a decrease of ceramide levels, a greater perioperative decline in BCAA, and the rise of circulating serine and glycine, mirroring glycemic control and inflammation improvement. In one study, 3-hydroxybutyrate was particularly identified as an early metabolic marker of long-term prognosis after surgery and proposed to increase current prognostic modalities and contribute to personalized treatment. CONCLUSIONS: Metabolomics helped in deciphering the metabolic response to weight loss treatments. Moving from association to causation is the next challenge to move to a further level of clinical application.
OBJECTIVE: To review the metabolomic studies carried out so far to identify metabolic markers associated with surgical and dietary treatments for weight loss in subjects with obesity. METHODS: The Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines were followed. RESULTS: Thirty-two studies successfully met the eligibility criteria. The metabolic adaptations shared by surgical and dietary interventions mirrored a state of starvation ketoacidosis (increase of circulating ketone bodies), an increase of acylcarnitines and fatty acid β-oxidation, a decrease of specific amino acids including branched-chain amino acids (BCAA) and (lyso)glycerophospholipids previously associated with obesity, and adipose tissue expansion. The metabolic footprint of bariatric procedures was specifically characterized by an increase of bile acid circulating pools and a decrease of ceramide levels, a greater perioperative decline in BCAA, and the rise of circulating serine and glycine, mirroring glycemic control and inflammation improvement. In one study, 3-hydroxybutyrate was particularly identified as an early metabolic marker of long-term prognosis after surgery and proposed to increase current prognostic modalities and contribute to personalized treatment. CONCLUSIONS: Metabolomics helped in deciphering the metabolic response to weight loss treatments. Moving from association to causation is the next challenge to move to a further level of clinical application.
Authors: Prapimporn Chattranukulchai Shantavasinkul; Michael J Muehlbauer; James R Bain; Olga R Ilkayeva; Damian M Craig; Christopher B Newgard; Laura P Svetkey; Svati H Shah; Alfonso Torquati Journal: Surg Obes Relat Dis Date: 2018-04-17 Impact factor: 4.734
Authors: Wasif Abidi; Eirini Nestoridi; Henry Feldman; Margaret Stefater; Clary Clish; Christopher C Thompson; Nicholas Stylopoulos Journal: Dig Dis Sci Date: 2019-08-05 Impact factor: 3.199
Authors: Magali Palau-Rodriguez; Sara Tulipani; Anna Marco-Ramell; Antonio Miñarro; Olga Jáuregui; Alex Sanchez-Pla; Bruno Ramos-Molina; Francisco J Tinahones; Cristina Andres-Lacueva Journal: PLoS One Date: 2018-06-01 Impact factor: 3.240
Authors: Cristina Menni; Marie Migaud; Gabi Kastenmüller; Tess Pallister; Jonas Zierer; Annette Peters; Robert P Mohney; Tim D Spector; Vincenzo Bagnardi; Christian Gieger; Steve C Moore; Ana M Valdes Journal: Obesity (Silver Spring) Date: 2017-07-31 Impact factor: 5.002
Authors: Judith Korner; Gary W Cline; Mark Slifstein; Pasquale Barba; Gina R Rayat; Gerardo Febres; Rudolph L Leibel; Antonella Maffei; Paul E Harris Journal: Mol Metab Date: 2019-02-27 Impact factor: 7.422
Authors: Ana Romo-Hualde; Ana E Huerta; Carlos J González-Navarro; Omar Ramos-López; María J Moreno-Aliaga; J Alfredo Martínez Journal: Lipids Health Dis Date: 2018-05-09 Impact factor: 3.876
Authors: Nadeeja N Wijayatunga; Valerie G Sams; John A Dawson; Matthew L Mancini; Gregory J Mancini; Naima Moustaid-Moussa Journal: Diabetes Metab Res Rev Date: 2018-09-19 Impact factor: 4.876